Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health, Inc. (JAGX) announced its participation at the Veterinary Cancer Society Collaborative Conference from April 19-22, 2023, promoting Canalevia-CA1, the first FDA conditionally approved treatment for chemotherapy-induced diarrhea (CID) in dogs. As of December 2022, the FDA expanded the annual treatment capacity from 70,000 to 80,000 dogs, enhancing the market potential for Canalevia-CA1. The drug is available through major U.S. veterinary distributors, reflecting an ongoing commitment to address significant unmet needs among veterinarians treating cancer patients.
Jaguar Health reported a substantial growth in prescription product net revenue, totaling $11.9 million for the year ending December 31, 2022, marking a 178.7% increase from $4.3 million in 2021. The fourth quarter of 2022 alone saw revenues of approximately $3.3 million, up 3.4% from the previous quarter. As of March 24, 2023, the company had a cash position of $15.3 million. Key initiatives include progressing through 80% enrollment in the Phase 3 OnTarget trial for crofelemer aimed at cancer therapy-related diarrhea, and plans for additional investigator-initiated studies in 2023. The investor webcast on March 27 will further detail these updates.
Jaguar Health, Inc. (NASDAQ:JAGX) has announced a change in the timing of its investor webcast, now scheduled for March 27, 2023 at 8:00 AM EDT, to discuss the fourth-quarter 2022 financial results and corporate updates. The company plans to file its Annual Report on March 24, 2023, for the fiscal year ended December 31, 2022. Jaguar focuses on developing plant-based prescription medications for gastrointestinal distress in humans and animals. Its subsidiary, Napo Pharmaceuticals, is conducting a pivotal Phase 3 trial for the drug crofelemer aimed at cancer patients experiencing diarrhea.
Jaguar Health (NASDAQ:JAGX) announced the appointment of Dr. Kelly Shanahan to its Scientific Advisory Board on March 23, 2023. Dr. Shanahan is a former clinician and a metastatic breast cancer patient advocate, bringing a unique perspective to the company's focus on cancer therapy-related diarrhea (CTD). She emphasized the importance of patient comfort and the development of crofelemer, a drug targeting CTD. The OnTarget Phase 3 clinical trial for crofelemer is expected to complete patient enrollment in Q2 2023, potentially paving the way for a significant advancement in supportive care for cancer patients.
Jaguar Health, Inc. (NASDAQ:JAGX) announces an investor webcast on March 27, 2023, at 8:30 AM EDT to discuss Q4 2022 financial results and corporate updates. The company will also file its Annual Report on March 24, 2023 for the fiscal year ending December 31, 2022. Jaguar Health specializes in developing plant-based medications for gastrointestinal distress, with a focus on its candidate, crofelemer, which is undergoing a Phase 3 clinical trial for cancer patients experiencing diarrhea.
Summary not available.
Jaguar Health announced the development of an AI-powered web portal to assist U.S. healthcare professionals with patient access to Mytesi (crofelemer), its FDA-approved drug for noninfectious diarrhea in HIV/AIDS patients. The initiative aims to mitigate access and reimbursement issues, specifically the burdensome prior authorization process. A recent AMA survey indicates that 88% of physicians face challenges with prior authorizations, which often delays patient care. By leveraging AI technology, Jaguar hopes to streamline this process and improve medication adherence, ultimately enhancing patient outcomes without collecting any Protected Health Information.
Jaguar Health (NASDAQ:JAGX) announced that its founder and CEO, Lisa Conte, will present at the BioTrinity 2023 conference in London on April 25, 2023. The presentation will focus on crofelemer, an oral botanical drug developed for short bowel syndrome (SBS) and congenital diarrheal disorders (CDD), which has received orphan drug designation from both the FDA and EMA. The event aims to raise awareness about rare diseases affecting millions globally. Jaguar's efforts aim to enhance crofelemer access in Europe through its subsidiary Napo Therapeutics.
Jaguar Health (NASDAQ:JAGX) announced that the U.S. FDA has granted Orphan Drug Designation to crofelemer for microvillus inclusion disease (MVID), a rare congenital diarrheal disorder. This designation adds to crofelemer's existing orphan status for short bowel syndrome (SBS) from both the FDA and European Medicines Agency. Jaguar aims to conduct proof-of-concept studies to reduce parenteral nutritional needs in patients with SBS or CDD throughout 2023. The Orphan Drug Act offers development incentives, including tax credits and seven-year marketing exclusivity for orphan drugs.
Jaguar Health (NASDAQ:JAGX) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application concerning methods for treating various types of diarrhea, including Bile Acid Diarrhea and Short Bowel Syndrome.
This is a significant step toward securing a U.S. patent for crofelemer, the active ingredient in its FDA-approved drug Mytesi, which helps alleviate noninfectious diarrhea in HIV/AIDS patients on ART. Jaguar currently holds around 145 patents with protection extending until 2031 and has another 55 pending patents globally, reinforcing its position in the botanical drug market.